BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020;21:E662. [PMID: 31963924 DOI: 10.3390/ijms21020662] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Niederle MB, Niederle B. Sporadische und familiäre neuroendokrine Tumoren des Magens. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_40] [Reference Citation Analysis]
2 Lahner E, Dilaghi E, Dottori L, Annibale B. Not all that is corpus restricted is necessarily autoimmune. Gut 2022. [DOI: 10.1136/gutjnl-2022-328959] [Reference Citation Analysis]
3 Gong EJ, Bang CS, Kim DK, Lee JJ, Baik GH. Use of Proton Pump Inhibitors and the Risk for the Development of Gastric Cancers: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions. Cancers (Basel) 2022;14:5172. [PMID: 36291956 DOI: 10.3390/cancers14205172] [Reference Citation Analysis]
4 Zhang ML, Fan YX, Meng R, Cai WK, Yin SJ, Zhou T, Huang YH, Wang P, Jiang FF, Yang M, He GH. Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies. Am J Clin Oncol 2022. [PMID: 36255347 DOI: 10.1097/COC.0000000000000949] [Reference Citation Analysis]
5 Yu Z, Wang A, Hu C, Yu T, Chen J. Type-1 Grade 2 Multi-Focal Gastric Neuroendocrine Tumors Secondary to Chronic Autoimmune Gastritis. Front Med 2022;9:856125. [DOI: 10.3389/fmed.2022.856125] [Reference Citation Analysis]
6 Seo SI. Long Term Proton Pump Inhibitor Use and Gastric Cancer. JDCR 2022;10:9-15. [DOI: 10.52927/jdcr.2022.10.1.9] [Reference Citation Analysis]
7 Couvelard A, Cros J. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs. Virchows Arch 2022. [PMID: 35278097 DOI: 10.1007/s00428-022-03306-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Watanabe H, Fujishima F, Komoto I, Imamura M, Hijioka S, Hara K, Yatabe Y, Kudo A, Masui T, Tsuchikawa T, Sakamoto K, Shiga H, Nakamura T, Nakaya N, Motoi F, Unno M, Sasano H. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors. Cancers (Basel) 2022;14:775. [PMID: 35159042 DOI: 10.3390/cancers14030775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Vaiphei K. Enterochromaffin-Like Cell and Associated Pathology. Interpretation of Endoscopic Biopsy - Gastritis, Gastropathies and Beyond 2022. [DOI: 10.1007/978-981-16-6026-9_5] [Reference Citation Analysis]
10 Niederle MB, Niederle B. Sporadische und familiäre neuroendokrine Tumoren des Magens. Springer Reference Medizin 2022. [DOI: 10.1007/978-3-662-61724-3_40-2] [Reference Citation Analysis]
11 Shin J, Oh TH, Kim JY, Shim JJ, Lee JL. Efficacy and Safety of the Cudrania tricuspidata Extract on Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Multicenter Study. J Clin Med 2021;10:5323. [PMID: 34830605 DOI: 10.3390/jcm10225323] [Reference Citation Analysis]
12 Rico K, Duan S, Pandey RL, Chen Y, Chakrabarti JT, Starr J, Zavros Y, Else T, Katona BW, Metz DC, Merchant JL. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. BMJ Open Gastroenterol 2021;8:e000765. [PMID: 34750164 DOI: 10.1136/bmjgast-2021-000765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
13 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021;74:2021-31. [PMID: 34018229 DOI: 10.1002/hep.31914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Wang L, Chen W, Lin X, Zhang Z, Wang N, Lv Y, Wang X, Gao Y. Protective Effect of Ultraviolet C Irradiation on the Gastric Mucosa of Rats with Chronic Gastritis Induced by Physicochemical Stimulations. Evid Based Complement Alternat Med 2021;2021:5189797. [PMID: 33815550 DOI: 10.1155/2021/5189797] [Reference Citation Analysis]
15 Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741. [PMID: 33975680 DOI: 10.1016/j.bpg.2021.101741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lock G, Oelckers M, Clauditz TS, Schrader J. Gastric NET Subtypes: Do We Need An Additional One? Z Gastroenterol 2021;59:255-8. [PMID: 33506449 DOI: 10.1055/a-1348-2727] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Niederle MB, Niederle B. Sporadische und familiäre neuroendokrine Tumoren des Magens. Springer Reference Medizin 2021. [DOI: 10.1007/978-3-662-61724-3_40-1] [Reference Citation Analysis]
18 Alhaddad O, Elsabaawy M, Elfauomy M, Elsabaawy D, Mansour T. Updates in drug-induced acute pancreatitis. Egypt Liver Journal 2020;10:49. [DOI: 10.1186/s43066-020-00059-3] [Reference Citation Analysis]
19 Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77:865-876. [PMID: 32702178 DOI: 10.1111/his.14220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
20 Liu M, Popa EC, Finnerty BM, Fahey TJ 3rd, Zarnegar R. Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms. Curr Gastroenterol Rep 2020;22:50. [PMID: 32797314 DOI: 10.1007/s11894-020-00788-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Tatsuguchi A, Hoshino S, Kawami N, Gudis K, Nomura T, Shimizu A, Iwakiri K. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa. Pathol Res Pract 2020;216:153113. [PMID: 32853950 DOI: 10.1016/j.prp.2020.153113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 2021;76:13-21. [PMID: 32718584 DOI: 10.1016/j.therap.2020.06.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]